NCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
Incyte Corporation
NGM Biopharmaceuticals, Inc
National Cancer Institute (NCI)
Case Comprehensive Cancer Center